Oxford Biomedica slashes FY revenue, margin guidance

(Sharecast News) - Oxford Biomedica on Friday slashed its full year revenue and margins forecast citing short‑term client ordering delays, programme deferrals and the later‑than‑expected readiness of its Durham, North Carolina facility.

It now expects 2026 revenue of £180m-200m compared with prior guidance of £220-240m.

Full-year EBITDA margin is expected to be mid-single-digit percentage - excluding one off costs - and low-single-digit on a reported basis, compared with the 10% guidance provided in March, reflecting lower than expected revenues and therefore absorption of operating costs.

Reporting by Frank Prenesti for Sharecast.com